AVITA Medical Inc (RCEL) gains 2.16% for July 21

Equities Staff  |

AVITA Medical Inc (NASDAQ: RCEL) shares gained 2.16%, or $0.42 per share, to close Wednesday at $19.83. After opening the day at $19.40, shares of AVITA Medical fluctuated between $19.94 and $19.28. 59,353 shares traded hands a decrease from their 30 day average of 267,165. Wednesday's activity brought AVITA Medical’s market cap to $492,634,370.

About AVITA Medical Inc

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

Visit AVITA Medical Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on AVITA Medical Inc and to follow the company’s latest updates, you can visit the company’s profile page here: AVITA Medical Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content